The combination of SGLT2 inhibitors and GLP-1 receptor agonists has been suggested to provide additive effects in reducing oxidative stress, which could enhance vascular repair, thus mitigating vascular comorbidities linked to obesity and type 2 diabetes [198]. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.